At a glance
- Originator Maruko Seiyaku
- Developer Azwell; Maruko Seiyaku
- Class Antiparkinsonians; Neuroprotectants; Small molecules
- Mechanism of Action Dopamine D1 receptor agonists; Dopamine D2 receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Heart failure; Hypertension; Parkinson's disease
Most Recent Events
- 22 Sep 2000 No-Development-Reported for Heart failure in Japan (Unknown route)
- 22 Sep 2000 No-Development-Reported for Hypertension in Japan (PO)
- 22 Sep 2000 No-Development-Reported for Parkinson's disease in Japan (Unknown route)